Johnson & Johnson
- SEC CIK
- 0000200406
- Latest filing
- Aug 6, 2026
Holdings in Q1 2024
Holdings as of Mar 31, 2024, filed May 10, 2024. Long positions only; changes compare share counts with Q4 2023.
- Positions
- 22
- −1 vs. Q4 2023
- Portfolio value
- $4.41B
- +$26.8M (+0.6%) vs. Q4 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| KVUEKenvue Inc. | Stock | 182,329,550 | $3.91B | 88.7% | 00.0% | Unchanged | History |
| FUSNFusion Pharmaceuticals Inc. | COM | 3,670,516 | $78.3M | 1.8% | 00.0% | Unchanged | History |
| CVRXCVRx, Inc. | COM | 4,103,430 | $74.7M | 1.7% | +607,855+17.4% | Added | History |
| PTGXProtagonist Therapeutics, Inc | COM | 2,449,183 | $70.9M | 1.6% | 00.0% | Unchanged | History |
| SWAVShockwave Medical, Inc. | COM | 166,812 | $54.3M | 1.2% | 00.0% | Unchanged | History |
| LEGNLegend Biotech Corp | SPONSORED ADS | 814,586 | $45.7M | 1.0% | 00.0% | Unchanged | History |
| MGTXMeiraGTx Holdings plc | COM | 6,641,064 | $40.3M | 0.9% | 00.0% | Unchanged | History |
| NBTXNanobiotix S.A. | SPONSORED ADS | 5,623,816 | $36.6M | 0.8% | 00.0% | Unchanged | History |
| NMRANeumora Therapeutics, Inc. | COM | 1,849,445 | $25.4M | 0.6% | 00.0% | Unchanged | History |
| FATEFate Therapeutics Inc | COM | 3,379,064 | $24.8M | 0.6% | 00.0% | Unchanged | History |
| PRCTPROCEPT BioRobotics Corp | COM | 357,939 | $17.7M | 0.4% | 00.0% | Unchanged | History |
| XNCRXencor Inc | COM | 748,062 | $16.6M | 0.4% | 00.0% | Unchanged | History |
| ARWRArrowhead Pharmaceuticals, Inc. | COM | 247,598 | $7.08M | 0.2% | 00.0% | Unchanged | History |
| VORVor Biopharma Inc. | COM | 1,074,658 | $2.55M | 0.1% | 00.0% | Unchanged | History |
| NNOXNano-X Imaging Ltd. | ORD SHS | 158,852 | $1.55M | <0.1% | −158,852−50.0% | Reduced | History |
| ALDXAldeyra Therapeutics, Inc. | COM | 299,669 | $979.9K | <0.1% | 00.0% | Unchanged | History |
| HLSQTessera Defense & Homeland Security Inc. | COM | 1,923,201 | $865.4K | <0.1% | −210,201−9.9% | Reduced | History |
| ACETAdicet Bio, Inc. | COM | 364,472 | $856.5K | <0.1% | −324,123−47.1% | Reduced | History |
| LABStandard Biotools Inc. | COM | 311,967 | $845.4K | <0.1% | +311,967 | New | History |
| CLSDClearside Biomedical, Inc. | COM | 169,629 | $259.5K | <0.1% | 00.0% | Unchanged | History |
| TCONTracon Pharmaceuticals, Inc. | COM NEW | 84,003 | $36.1K | <0.1% | 00.0% | Unchanged | History |
| SENSSenseonics Holdings, Inc. | COM | 54,621 | $29.0K | <0.1% | 00.0% | Unchanged | History |
Sold out since Q4 2023 (2)
Positions held at the end of Q4 2023 that are gone from this filing.